BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Has Consensus Target Price of $31.38 According to Brokerages
BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus "Hold" rating from eleven analysts, with an average 12-month price target of $31.38. Despite this, the stock opened at $37.30, trading above its average price objective. The company recently surpassed earnings expectations, reporting $0.91 EPS against a $0.03 consensus and revenues of $28.47 million, exceeding the $27.80 million forecast.
[425] BIOLIFE SOLUTIONS INC Business Combination Communication | BLFS SEC Filing - Form 425
This SEC Form 425 filing details the business combination between BioLife Solutions Inc. (BLFS) and Repligen Corporation, where Repligen will acquire BioLife for cash and Repligen common shares. The merger is subject to BioLife stockholder approval and is facing two shareholder lawsuits alleging misrepresentation in the proxy statement. The filing includes supplemental disclosures to address these concerns and provides updated information regarding executive compensation and severance packages post-merger.
Two parties report shared voting power over more than 5% of BioLife Solutions (BLFS) shares.
Glazer Capital, LLC and Paul J. Glazer have reported shared beneficial ownership of 2,685,520 common shares, representing 5.49% of BioLife Solutions (BLFS). This Schedule 13G filing indicates that both parties have shared voting and dispositive power over these shares, with Glazer Capital acting as the investment manager for the funds holding them. Additionally, Glazer Capital Enhanced Master Fund, Ltd. has the right to receive or direct proceeds from the sale of over 5% of BioLife's outstanding common stock.
BioLife Solutions, Inc. (BLFS) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of BioLife Solutions, Inc. (BLFS), including its current stock price, trading activity, key financial metrics, and company profile. It highlights the company's focus on bioproduction products and services for the cell and gene therapy industry, along with performance benchmarks against the S&P 500 and analyst insights.
BioLife Solutions (BLFS) CEO uses shares to cover taxes
BioLife Solutions CEO, Roderick De Greef, had 2,775 shares of company common stock withheld to satisfy tax obligations related to vested restricted stock units. This transaction, which occurred on September 18, 2026, at $36.69 per share, was a tax withholding event and not a market sale. Following this, De Greef directly holds 728,196 shares of BLFS common stock.
BioLife Solutions (BLFS) withholds 564 insider shares for taxes
BioLife Solutions' EVP & Chief Scientific Officer, Mathew Aby J., had 564 shares of common stock withheld on September 18, 2026, to cover tax obligations from restricted stock unit vesting. The shares were valued at $36.69 each, and after this transaction, Mr. Aby J. directly holds 387,269 shares of BLFS. This withholding was not part of a Rule 10b5-1 trading plan.
Biolife Solutions stock hits 52-week high at $38.10
BioLife Solutions (BLFS) stock recently hit a 52-week high of $38.10, driven by a 97% surge over the last six months, although it is now considered overvalued by InvestingPro. The company's financial health is rated "GREAT," and it is undergoing a merger with Repligen Corporation, which will acquire BioLife for $11.25 in cash and 0.1442 shares of Repligen stock per BioLife share. Following the merger announcement, TD Cowen downgraded BioLife Solutions from Buy to Hold, adjusting its price target to $31 per share.
Tidal Investments LLC Buys Shares of 29,012 BioLife Solutions, Inc. $BLFS
Tidal Investments LLC has acquired 29,012 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $819,000, establishing a 0.06% stake in the company. Institutional investors now collectively own 93.24% of BioLife Solutions. The company recently reported strong quarterly results, exceeding analyst expectations for both revenue and EPS, though analysts maintain a "Hold" rating with a consensus price target of $31.38.
Squarepoint Ops LLC Purchases New Position in BioLife Solutions, Inc. $BLFS
Squarepoint Ops LLC has acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS), purchasing 132,942 shares valued at $3.75 million. This move comes as institutional investors now own 93.24% of the company, despite several analysts downgrading the stock to "Hold" or "Neutral" with revised price targets. BioLife Solutions recently surpassed earnings and revenue expectations, but its stock is trading near its 52-week high, with an average analyst target price of $31.38.
BioLife Solutions EVP Aby J. Mathew Withholds 627 Shares for RSU Tax on September 8, 2026
BioLife Solutions EVP and Chief Scientific Officer, Aby J. Mathew, withheld 627 common stock shares valued at $35.38 each on September 8, 2026, to cover tax obligations related to the release of restricted stock units (RSUs). This transaction, filed on a Form 4, indicates that Mathew directly holds 387,833 common stock shares after the withholding. The filing confirms that the transaction was for tax purposes and not executed under a Rule 10b5-1(c) trading plan.
BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Average Recommendation of "Hold" from Analysts
Analysts have issued an average "Hold" recommendation for BioLife Solutions (NASDAQ:BLFS), with a consensus 12-month price target of $31.38, which is below the current stock price of $34.93. Recent downgrades from several brokerages reflect this cautious outlook, despite the company exceeding its latest quarterly earnings and revenue expectations. Institutional investors hold a significant majority of the company's shares.
BioLife Solutions merger with Repligen advances as antitrust waiting period ends
BioLife Solutions announced that the Hart-Scott-Rodino Antitrust Improvements Act waiting period for its proposed acquisition by Repligen Corporation has expired, satisfying a key merger condition. Repligen will acquire BioLife for $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share. The merger remains subject to BioLife stockholder approval, with a special meeting scheduled for October 5, 2026.
Form 8K BioLife Solutions Inc For: 10 September By Investing.com
This article announces the filing of a Form 8K by BioLife Solutions Inc. on September 10. The brief update from Investing.com is a standard notification about corporate filings. No specific details about the content of the 8K are provided within this particular news item.
BioLife Solutions Inc. (BLFS) Key Financial Ratios – Valuation, Profitability & More
This article provides a detailed analysis of BioLife Solutions Inc. (BLFS) key financial ratios, covering valuation, profitability, growth, solvency, and operating efficiency. It presents both quarterly and annual data, including comparisons with peer medians. The report highlights BLFS's performance in revenue, net profit, return on equity, and other critical financial metrics.
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. The firm is examining whether BioLife's board failed to secure the best possible price for shareholders, conducted a fair sales process, and disclosed all material information. Halper Sadeh LLC encourages BioLife shareholders to contact them to discuss their rights and options.
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. The firm is examining whether BioLife's board violated federal securities laws or breached fiduciary duties by potentially failing to secure the best price, ensure a fair sales process, or disclose all material information. Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights.
BioLife Solutions (NASDAQ:BLFS) Reaches New 52-Week High - Still a Buy?
BioLife Solutions (NASDAQ:BLFS) recently reached a new 52-week high of $38.10, with a market capitalization of $1.86 billion, despite analysts maintaining a "Hold" rating and an average price target of $31.38. The company reported a significant earnings beat of $0.91 per share against an estimate of $0.03, with revenues of $28.47 million. Institutional investors hold a substantial 93.24% of the stock, with the California State Teachers’ Retirement System notably increasing its position.
238,521 Shares in BioLife Solutions, Inc. $BLFS Acquired by Ranger Investment Management L.P.
Ranger Investment Management L.P. acquired a new position of 238,521 shares in BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $6.7 million during the second quarter, representing 0.49% of the company's stock. Other institutional investors also adjusted their holdings, contributing to institutional ownership of 93.24%. Despite opening near its 52-week high, BioLife Solutions holds a consensus "Hold" rating from analysts with an average price target of $31.38, following several recent downgrades.
Bank of America Corp DE Increases Stake in BioLife Solutions, Inc. $BLFS
Bank of America Corp DE significantly increased its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 73.4% in the first quarter, now owning 904,103 shares valued at approximately $17.25 million. Other institutional investors also adjusted their positions in the medical equipment provider, which recently reported strong quarterly earnings, beating consensus estimates. Despite several analyst downgrades to "Hold," institutional investors collectively hold 93.24% of BLFS shares.
Summit Creek Advisors LLC Acquires New Position in BioLife Solutions, Inc. $BLFS
Summit Creek Advisors LLC has acquired a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) during the second quarter, purchasing 180,544 shares valued at approximately $5.1 million, making BLFS its 28th largest position. Institutional investors and hedge funds collectively own 93.24% of the company, though analyst sentiment remains mixed with an average "Hold" rating. BioLife Solutions recently reported strong quarterly EPS of $0.91, significantly exceeding estimates, while facing insider selling from a major shareholder.
Diamond Hill Capital Management LLC Investment Advisor Acquires New Stake in BioLife Solutions, Inc. $BLFS
Diamond Hill Capital Management LLC Investment Advisor has acquired a new stake of 153,887 shares in BioLife Solutions, Inc. (NASDAQ:BLFS), valued at approximately $4.35 million. This purchase represents 0.31% of BioLife Solutions, with institutional investors now owning 93.24% of the company. Despite BioLife Solutions beating analysts' EPS and revenue estimates in its latest quarterly report, the consensus analyst rating for the stock has shifted to "Hold" with a target price of $31.38.
Short Interest in BioLife Solutions, Inc. (NASDAQ:BLFS) Rises By 59.1%
Short interest in BioLife Solutions (NASDAQ:BLFS) surged by 59.1% in July, reaching 4.54 million shares, which represents 9.5% of its outstanding shares. This increase comes as analysts have become more cautious, with several downgrading the stock to "Hold" or "Neutral" and reducing price targets to around $31. Despite these concerns, BioLife Solutions recently surpassed quarterly earnings and revenue expectations.
Biolife Solutions stock hits 52-week high at 35.36 USD
BioLife Solutions Inc. (BLFS) has reached a new 52-week high of $35.36, representing a significant surge of nearly 98% from its 52-week low, driven by strong investor confidence. Despite this, InvestingPro data suggests the stock is currently in overbought territory and appears overvalued according to its Fair Value analysis. Additionally, TD Cowen recently downgraded BioLife Solutions to a Hold rating following Repligen's announcement to acquire the company for $31 per share.
BioLife’s Sharp Swing To Profit Might Change The Case For Investing In BioLife Solutions (BLFS)
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a net income of US$45.10 million and improving EPS from a loss of US$0.32 to earnings of US$0.92. This sharp increase in profitability, coupled with the pending US$1.6 billion acquisition by Repligen, could reshape the company's investment profile. However, investors should also consider the business's reliance on a concentrated customer base and the long-term demand for cell and gene therapy tools.
Roubaix Capital, LLC's BioLife Solutions Inc(BLFS) Holding History
This article details Roubaix Capital, LLC's investment history in BioLife Solutions Inc (BLFS). As of June 30, 2026, Roubaix Capital held over 309,000 shares of BLFS, valued at $8.74 million, representing 3.14% of their portfolio. The firm has made multiple purchases and sales of BLFS since 2019, resulting in an estimated gain of $4.38 million.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by Brokerages
BioLife Solutions (NASDAQ:BLFS) has received an average "Hold" recommendation from brokerages, with the majority of analysts issuing a hold rating. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite positive institutional investor activity, insiders have sold a significant number of shares in the last quarter.
BioLife Solutions, Inc. (BLFS) Stock Forecasts
Argus has raised its target price for BioLife Solutions Inc. (BLFS) to $37.00. The company, a life sciences firm, specializes in bioproduction products and services aimed at enhancing quality and mitigating risks in biologic manufacturing, distribution, and transportation within the cell and gene therapy industry. This update suggests a positive outlook for BLFS by Argus.
BioLife Solutions (NASDAQ:BLFS) Hits New 12-Month High - Time to Buy?
BioLife Solutions (NASDAQ:BLFS) recently hit a new 52-week high of $34.93, trading nearly flat at $34.64. The company reported strong quarterly earnings of $0.91 per share, significantly beating the consensus estimate of $0.03, and revenue of $28.47 million, exceeding expectations. Despite insider selling activity totaling $28.1 million over the last quarter, institutional investors hold a substantial 93.24% stake in the company, with analyst sentiment generally mixed, holding a consensus "Hold" rating and a target price below the current share price.
BioLife Solutions Cut to Hold From Buy by Benchmark
Benchmark downgraded BioLife Solutions (BLFS) stock from Buy to Hold. This adjustment reflects a revised outlook from the firm regarding the company's investment potential.
Why BioLife Solutions (BLFS) Is Up 7.8% After Swinging To Q2 Profitability And What's Next
BioLife Solutions (BLFS) reported a significant swing to profitability in Q2 2026, with sales up to US$28.47 million and net income of US$45.1 million, driven by its role as a supplier to the cell and gene therapy sector. The company is set to be acquired by Repligen for US$1.6 billion, a deal expected to close in Q4 2026. This financial improvement and the impending acquisition reframe its investment outlook, though risks like customer concentration remain.
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss of US$15.84 million to a net income of US$45.10 million, with sales increasing to US$28.47 million. This improved financial performance follows the announcement of a US$1.6 billion acquisition by Repligen, shifting the company's immediate focus towards deal completion and integration. Despite the strong quarter, the article highlights the importance of customer concentration and execution on new products as key short-term factors, with analysts giving varied fair value estimates for the stock.
BioLife Solutions, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioLife Solutions, Inc. has released its earnings summary for the quarter that ended on June 30. The full article provides detailed results of the company's financial performance during this period.
ETFs Investing in BioLife Solutions, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of BioLife Solutions, Inc. (BLFS). The ETFs are primarily focused on small-cap companies and are managed by various financial institutions like BlackRock, State Street Corp., and The Vanguard Group. The provided table includes details such as market value, weight of BLFS stock in the fund, issuer, management style, expense ratio, assets under management (AUM), and historical performance.
Royal Bank of Canada Purchases 66,010 Shares of BioLife Solutions, Inc. $BLFS
Royal Bank of Canada increased its stake in BioLife Solutions (NASDAQ:BLFS) by 8.1%, purchasing an additional 66,010 shares, bringing its total to 885,298 shares valued at approximately $16.9 million. This transaction comes as other institutional investors have adjusted their positions, and despite a major insider sale, BioLife Solutions reported quarterly earnings per share of $0.04, beating estimates. Analysts maintain a "Hold" rating with a consensus target price of $31.38, while the stock trades at $33.93.
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a profit of US$45.10 million on US$28.47 million in sales. This positive financial performance comes shortly after the announcement of its US$1.6 billion acquisition by Repligen. The article highlights that while the improved earnings are positive, risks such as customer concentration and execution on new products remain, and the acquisition shifts the focus to deal completion and integration.
BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen
BioLife Solutions (NASDAQ: BLFS) has reported strong Q2 2026 financial results, with revenue reaching $28.5 million and net income from continuing operations at $45.1 million, largely due to a significant income tax benefit. The company also announced a cash-and-stock merger agreement with Repligen, where each BioLife share will be exchanged for $11.25 in cash and 0.1442 Repligen shares, with the merger expected to close in Q4 2026. This move follows BioLife's recent divestiture of its SAVSU business and aims to integrate its bioproduction products and services into Repligen's operations.
Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q2 Revenue $28.5M, vs. FactSet Est of $27.8M
BioLife Solutions, Inc. (BLFS) announced its Q2 revenue of $28.5 million, surpassing the FactSet estimate of $27.8 million. The company's stock, listed on Nasdaq, closed at $33.93 on August 6th, marking a 0.38% increase for the day. This positive earnings report follows a series of recent downgrades from several analysts and an acquisition agreement by Repligen Corporation for approximately $1.6 billion.
BioLife Solutions Reports Second Quarter 2026 Financial Results
BioLife Solutions announced its Q2 2026 financial results, reporting total revenue of $28.5 million, a 21% increase over Q2 2025, and GAAP net income of $45.1 million, which included a significant non-cash income tax benefit. The company also confirmed its pending acquisition by Repligen for approximately $1.5 billion, expected to close in Q4 2026. This acquisition will result in BioLife ceasing to be a publicly traded company.
BioLife Solutions set to report earnings under takeover cloud
BioLife Solutions is set to report second-quarter earnings under the shadow of a $1.5 billion acquisition agreement by Repligen Corporation. Analysts have largely downgraded BioLife's stock to "Hold" with price targets around the acquisition price of $31 per share. Investors will be focused on whether the earnings validate Repligen's valuation and any updates on the deal's closure, which is expected in Q4 2026.
Biolife Solutions stock hits 52-week high at 33.18 USD
BioLife Solutions Inc. (NASDAQ:BLFS) stock recently hit a 52-week high of $33.18, reflecting a 56.33% increase over the past year and a current market capitalization of $1.61 billion. Despite strong revenue growth and analyst predictions of profitability, InvestingPro analysis suggests the stock may be overvalued. Additionally, Repligen announced plans to acquire BioLife Solutions for $31 per share, leading to a downgrade from TD Cowen.
Repligen Corporation (BLFS) sets cash and stock terms for BioLife Solutions buyout
Repligen Corporation has entered into an Agreement and Plan of Merger to acquire BioLife Solutions for $11.25 in cash plus 0.1442 shares of Repligen common stock per BioLife share. The transaction is a strategic move in the cell therapy market, pending regulatory and BioLife stockholder approvals, with an expected closing in Q4 2026. Repligen plans to file a Form S-4 registration statement, including a joint proxy statement/prospectus, for BioLife stockholders to review.
Repligen to acquire BioLife Solutions in two-step merger; employee video details timeline
BioLife Solutions and Repligen are set to merge through a two-step process, forming a Repligen subsidiary, with an expected closing in Q4 pending approvals. The first step involves Repligen's Merger Sub 1 merging into BioLife, making BioLife a direct subsidiary, followed immediately by BioLife merging into Merger Sub 2. Repligen's CEO shared a video with BioLife staff detailing the strategic rationale and cultural fit.
BioLife Solutions, Inc. Revenue Breakdown – NASDAQ:BLFS
This article provides a revenue breakdown for BioLife Solutions, Inc. (NASDAQ: BLFS). Last year, the company generated $96.21 million USD, with its top-performing segment, Bioproduction Products and Services, contributing the entire amount. The United States was the primary revenue source, accounting for $76.97 million USD last year.
BioLife Solutions Inc (BLFS) Valuation: PE, PB & Fair Value Analysis
BioLife Solutions Inc (BLFS) currently has a valuation score of 8.75, placing it 62nd out of 199 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -508.27, which is significantly below its recent high and slightly above its recent low. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Hsbc Holdings PLC Purchases Shares of 45,576 BioLife Solutions, Inc. $BLFS
HSBC Holdings PLC has acquired 45,576 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) valued at about $874,000, representing a 0.09% stake in the medical equipment provider. Despite the company recently exceeding earnings expectations with $0.04 EPS versus a $0.01 estimate and $27.50 million in revenue, analysts have mostly downgraded the stock to a "Hold" rating with a consensus price target of $31.38. This comes amidst significant insider selling, with 1.2 million shares worth approximately $28.1 million offloaded in the past 90 days.
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
This article summarizes changes in analyst ratings and price targets for several U.S.-listed companies as reported by Reuters on a Friday. Key changes include Stephens cutting BioLife Solutions to equal weight, Leerink Partners raising Gossamer Bio to outperform, and TD Cowen cutting Intuit to hold. Additionally, JP Morgan raised International Paper to overweight, and Canaccord Genuity cut MapLight Therapeutics' target price.
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
Repligen and BioLife Solutions recently held an M&A call to discuss potential combinations or partnerships in bioprocessing and cell and gene therapy tools. This new corporate activity comes as Repligen's shares show mixed returns, and investors will be looking for clarity on deal structure, integration plans, and the impact on strategic priorities. The article highlights the risks and rewards, including integration challenges and expanded product portfolios, that investors should consider.
Biolife Solutions stock hits 52-week high at 32.24 USD By Investing.com
BioLife Solutions (BLFS) recently reached a 52-week high of $32.24, highlighting a significant upward trend with a 34.8% stock price increase over the last year. However, despite impressive Q1 2026 revenue growth and a "GREAT" financial health score from InvestingPro, data suggests the stock might be overvalued. The company is also set to be acquired by Repligen (RGEN) for $31 per share, leading to a downgrade from Buy to Hold by TD Cowen.
BioLife Solutions, Inc. (BLFS) Investor Outlook: Navigating Growth with a 4.9% Upside Potential
BioLife Solutions, Inc. (BLFS) is a healthcare company specializing in medical instruments and supplies for cell and gene therapy, with a market cap of $1.46 billion. Despite a current EPS of -0.24 and negative return on equity due to ongoing investments, analysts project a 4.9% upside potential from its current share price of $29.79, with an average target of $31.25. The company exhibits strong revenue growth of 24.70% and positive technical indicators, and analyst sentiment is cautiously optimistic with 3 buy ratings and 6 hold ratings.
Biolife Solutions stock hits 52-week high at 32.24 USD
Biolife Solutions stock reached a 52-week high of $32.24, showing a significant 34.8% increase over the past year. The company boasts a 1.56 billion USD market cap, nearly 30% revenue growth, and a "GREAT" financial health score from InvestingPro, though its stock may be overvalued by InvestingPro's Fair Value analysis. Additionally, Repligen plans to acquire BioLife Solutions for $31 per share, leading TD Cowen to downgrade the stock from Buy to Hold.
